Bimekizumab

From WikiProjectMed
Jump to navigation Jump to search
Bimekizumab
Monoclonal antibody
TypeWhole antibody
SourceHumanized
TargetIL17A, IL17F, IL17AF
Clinical data
Trade namesBimzelx
License data
Pregnancy
category
ATC code
Legal status
Legal status
  • AU: S4 (Prescription only) [1]
  • EU: Rx-only [2]
Identifiers
CAS Number
UNII
KEGG

Bimekizumab, sold under the brand name Bimzelx, is a humanized anti-IL17A, anti-IL-17F, and anti-IL17AF monoclonal antibody[2][3] that is used to treat plaque psoriasis.[2]

The most common side effects include upper respiratory tract infections (nose and throat infection) and oral candidiasis (thrush, a fungal infection in the mouth or throat).[2]

Bimekizumab was approved for medical use in the European Union in August 2021.[2][4]

Medical uses

Bimekizumab is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.[2]

History

This drug is being developed by Belgian pharmaceutical company UCB. Phase III trials have demonstrated that bimekizumab is superior to not only adalimumab[5] but also secukinumab[6] for the treatment of plaque psoriasis.

Names

Bimekizumab is the international nonproprietary name (INN).[7]

References

  1. ^ a b "Bimzelx". Therapeutic Goods Administration (TGA). 7 April 2022. Retrieved 24 April 2022.
  2. ^ a b c d e f "Bimzelx EPAR". European Medicines Agency (EMA). 23 June 2021. Retrieved 24 August 2021. Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
  3. ^ Lim SY, Oon HH (2019-05-13). "Systematic review of immunomodulatory therapies for hidradenitis suppurativa". Biologics. 13: 53–78. doi:10.2147/BTT.S199862. PMC 6526329. PMID 31190730.
  4. ^ "UCB Announces European Commission Approval of Bimzelx (bimekizumab) for the Treatment of Adults with Moderate to Severe Plaque Psoriasis". UCB (Press release). 24 August 2021. Retrieved 24 August 2021.
  5. ^ Warren, Richard B.; Blauvelt, Andrew; Bagel, Jerry; Papp, Kim A.; Yamauchi, Paul; Armstrong, April; Langley, Richard G.; Vanvoorden, Veerle; De Cuyper, Dirk; Cioffi, Christopher; Peterson, Luke (2021-07-08). "Bimekizumab versus Adalimumab in Plaque Psoriasis". New England Journal of Medicine. 385 (2): 130–141. doi:10.1056/NEJMoa2102388. ISSN 0028-4793. PMID 33891379. S2CID 233372177.
  6. ^ Reich, Kristian; Warren, Richard B.; Lebwohl, Mark; Gooderham, Melinda; Strober, Bruce; Langley, Richard G.; Paul, Carle; De Cuyper, Dirk; Vanvoorden, Veerle; Madden, Cynthia; Cioffi, Christopher (2021-07-08). "Bimekizumab versus Secukinumab in Plaque Psoriasis". New England Journal of Medicine. 385 (2): 142–152. doi:10.1056/NEJMoa2102383. ISSN 0028-4793. PMID 33891380. S2CID 233370455.
  7. ^ World Health Organization (2014). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 72". WHO Drug Information. 28 (3). hdl:10665/331112.

Further reading

  • Reis J, Vender R, Torres T (August 2019). "Bimekizumab: The First Dual Inhibitor of Interleukin (IL)-17A and IL-17F for the Treatment of Psoriatic Disease and Ankylosing Spondylitis". BioDrugs. 33 (4): 391–9. doi:10.1007/s40259-019-00361-6. PMID 31172372. S2CID 174812750.

External links

  • "Bimekizumab". Drug Information Portal. U.S. National Library of Medicine.